Search research articles
Contact Us
Filters
Showing results (371-380 of 527) with videos related to
Page
of 53
Sort By:
Molecular Cancer Therapeutics
|
July 5, 2012
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib
Ondrej Kalous, Dylan Conklin, Amrita J Desai, et al.
Neuropsychologia
|
December 23, 2023
Will you read how I will read? Naturalistic fMRI predictors of emergent reading
Elizabeth K Wat, David C Jangraw, Emily S Finn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2016
Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
Annette Künkele, Agne Taraseviciute, Laura S Finn, et al.
Anti-Cancer Drugs
|
November 29, 2007
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
D Ross Camidge, S Gail Eckhardt, Lia Gore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2014
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT
Neil A O'Brien, Karen McDonald, Luo Tong, et al.
Liver Cancer
|
August 8, 2024
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, et al.
Hepatic Oncology
|
September 8, 2018
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial
Lorenza Rimassa, Camillo Porta, Ivan Borbath, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
May 24, 2024
Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel
Lindsay M Thornton, Nadine Abi-Jaoudeh, Howard J Lim, et al.
Clinical Breast Cancer
|
December 15, 2019
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2
Hope S Rugo, Richard S Finn, Karen Gelmon, et al.
Cancer Treatment Reviews
|
December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development
R Stahel, J Bogaerts, F Ciardiello, et al.
Page
of 53
Search research articles
Search
Showing results (371-380 of 527) with videos related to
Sort By:
Page
of 53
Molecular Cancer Therapeutics
|
July 5, 2012
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib
Ondrej Kalous, Dylan Conklin, Amrita J Desai, et al.
Neuropsychologia
|
December 23, 2023
Will you read how I will read? Naturalistic fMRI predictors of emergent reading
Elizabeth K Wat, David C Jangraw, Emily S Finn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2016
Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
Annette Künkele, Agne Taraseviciute, Laura S Finn, et al.
Anti-Cancer Drugs
|
November 29, 2007
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
D Ross Camidge, S Gail Eckhardt, Lia Gore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2014
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT
Neil A O'Brien, Karen McDonald, Luo Tong, et al.
Liver Cancer
|
August 8, 2024
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, et al.
Hepatic Oncology
|
September 8, 2018
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial
Lorenza Rimassa, Camillo Porta, Ivan Borbath, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
May 24, 2024
Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel
Lindsay M Thornton, Nadine Abi-Jaoudeh, Howard J Lim, et al.
Clinical Breast Cancer
|
December 15, 2019
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2
Hope S Rugo, Richard S Finn, Karen Gelmon, et al.
Cancer Treatment Reviews
|
December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development
R Stahel, J Bogaerts, F Ciardiello, et al.
Page
of 53